Searchable abstracts of presentations at key conferences in endocrinology

ea0063p446 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Prevalence of non-carcinoid syndrome (non-CS) diarrhoea in patients with neuroendocrine tumours (NETs): a systematic literature review (SLR)

Khan Mohid S , Walter Thomas , Buchanan-Hughes Amy , Keeber Lucie , Feuilly Marion , Grande Enrique

Background: Approximately 20% of NET patients develop CS, characterised by diarrhoea and flushing. However, CS is not the only cause of diarrhoea among NET patients. Non-CS causes should be considered to allow for appropriate management. We investigated the reported occurrence of diarrhoea from various non-CS causes in patients with gastroenteropancreatic NETs (GEP-NETs), to explore the need for differential diagnosis (DDx) of NET diarrhoea.Methods: MEDL...

ea0052p16 | (1) | UKINETS2017

Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR

Pavel Marianne , Cella David , Beaumont Jennifer , Hudgens Stacie , Marteau Florence , Feuilly Marion , Gabriel Sylvie , Houchard Aude , Ramage John , Horsch Dieter , Kulke Matthew

Background: The safety and efficacy of telotristat ethyl (TE) in patients (pts) with metastatic neuroendocrine tumors (NETs) and carcinoid syndrome (CS) not adequately controlled with somatostatin analogs (SSAs) have been demonstrated. TE-treated pts showed significantly greater reductions in bowel movement (BM) frequency and more presented with durable response than placebo (PBO)-treated pts. These post-hoc analyses examined the relationship between improvements in symptoms a...